Point-of-care breath diagnosis powered by nanosensors and AI
We develop a rapid, non-invasive point-of-care breath analysis platform combining proprietary nanosensors with AI. Our technology creates a novel biological feature space from breath biomarkers, enabling disease detection beyond conventional methods. We are focused on early lung cancer detection and liver fibrosis staging, and are currently in the clinical phase across 8 medical centers. Based on thousands of breath samples collected, our results demonstrate performance superior to current non-invasive tests, including high sensitivity for early-stage lung cancer (Stages I-II). Backed by EIC grants and Google, Nanose Medical is advancing a scalable diagnostic platform designed to enable faster, more accessible clinical decision-making.